ExomeDNAExomeDNA
Read your report

Age-Related Eyesight Decline and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder

Reviewed by ExomeDNA Editorial Process · [/methodology/editorial-process]

Last reviewed: 2026-05-29

DISCLAIMER: This content is educational and informational. For health decisions, consult a clinician.

Age-Related Eyesight Decline is a Longevity & Aging trait that captures the gradual reduction in visual function that commonly emerges across middle and later life. Research suggests that genetic factors contribute to individual differences in how quickly or severely eyesight changes with age, with signals found near genes involved in structural development and retinal signaling. This page covers the biology behind this trait, what current research has found, and how general wellness habits relate to long-term eye health.

Age-related eyesight decline refers to the broad pattern of visual changes — including reduced acuity, contrast sensitivity, and ease of adaptation — that tend to accumulate as people get older. While some degree of visual change is a normal part of aging, individuals vary substantially in its timing and severity. Genetics research has begun identifying regions of the genome that may influence those individual differences, though the science remains in early stages.

Genome-wide association research has uncovered several genomic regions where common variants appear linked to patterns of age-related visual change. The strongest signals in this dataset sit near genes with roles in tissue development, growth factor signaling, and sensory function.

The highest-ranked genetic signal in this trait falls near BMP3, a gene in the bone morphogenetic protein family. BMP family members are broadly involved in the development of connective tissue structures throughout the body, and the strongest association signal is located within roughly 1 kilobase of BMP3's genomic position on chromosome 4. A second highly ranked signal lies near BMP4, also a bone morphogenetic protein family member, located on chromosome 14. BMP4 has been studied in the context of ocular development, including regulation of eye size and certain structural properties of ocular tissue.

A third notable signal falls near BMP2 on chromosome 20, which rounds out a cluster of BMP-family associations in this trait. While these genomic findings identify regions of statistical association, they do not establish that BMP genes are directly causing age-related visual change — the associations reflect population-level patterns, and the underlying biology remains an area of ongoing inquiry.

Beyond the BMP cluster, signals also appear near VIPR2 (chromosome 7), a gene encoding a receptor for vasoactive intestinal peptide with roles in circadian rhythm regulation and neuroprotection; TLL1 (chromosome 4), a metalloprotease involved in extracellular matrix processing; ADAMTSL1 (chromosome 9), a secreted glycoprotein with roles in connective tissue and extracellular matrix assembly; and RASGRF1 (chromosome 15), a guanine nucleotide exchange factor with documented involvement in retinal function in animal models.

Of particular note is RGR (chromosome 10), which encodes retinal G protein-coupled receptor — a protein expressed in the retinal pigment epithelium with a direct functional role in the visual cycle. The presence of a genomic signal near RGR is biologically plausible in the context of age-related visual change, though the moderate confidence rating for this trait reflects that definitive causal mechanisms have not been established from the available data.

Research base: Moderate.

KEY STAT A large-scale analysis of UK Biobank phenotype data identified latent structure across hundreds of health and physical traits, including visual decline patterns, by applying confirmatory factor analysis to distill overlapping phenotype signals into coherent biological groupings (Carey 2024[1]).

What the Research Says

The primary evidence base for this trait comes from a large UK Biobank analysis that applied confirmatory factor analysis to distill patterns from hundreds of measured phenotypes into underlying biological factors. The study identified a factor — labeled Factor 27 in the analysis — that captures the shared variance across visual decline measures with aging (Carey 2024[1]).

Because this trait is derived from a factor-analytic construct rather than a single direct phenotype measurement, interpretation requires some care. The genetic signals identified through this approach reflect associations with the latent factor, not with a specific clinical outcome such as macular degeneration or cataract formation. This is an important distinction: studies suggest that genetic influences on broad visual aging patterns do exist, but the specific mechanisms linking these variants to visual outcomes in individuals remain incompletely characterized.

For this trait, ExomeDNA reports a moderate confidence classification. This means the underlying genomic signals are real and replicable at the study level, but the translation from population-level statistical associations to individual-level predictive certainty warrants appropriate hedging. People with elevated polygenic scores on this trait are not certain to experience faster visual decline, nor are people with lower scores guaranteed protection.

KEY STAT The UK Biobank study underlying this trait analyzed data from hundreds of thousands of participants, with factor analysis revealing coherent clusters of phenotypic variation across aging-related outcomes including visual function (Carey 2024[1]).

Age-related visual changes are among the most commonly reported shifts in physical function as people move through their 50s, 60s, and beyond. Common patterns include increasing difficulty with near vision (presbyopia), slower adaptation when moving between bright and dim environments, greater sensitivity to glare, and reduced contrast detection.

Beyond these near-universal changes, more significant conditions — including age-related macular degeneration, glaucoma, and lens clouding — represent the more severe end of the spectrum of age-related visual decline. These conditions involve distinct biological pathways and have their own genetic architectures; the broad trait covered here is not equivalent to any single clinical condition.

The "higher is detrimental" directionality for this trait means that higher polygenic scores are associated with patterns more consistent with greater age-related visual change. As with all polygenic traits, genetic factors represent one part of a larger picture that includes environmental exposures, lifestyle, and access to care.

Important general health literacy around eye aging includes:

  • UV protection: Chronic ultraviolet exposure to the lens and retina is associated in epidemiological research with accelerated structural changes. Sunglasses with UV-A and UV-B protection are widely recommended for outdoor use.
  • Dietary patterns: Observational research has associated diets rich in leafy green vegetables — which contain lutein and zeaxanthin — and omega-3 fatty acids with patterns of retinal health. These associations are not mechanistically proven to prevent decline, but they are consistent with general guidance on aging and eye health.
  • Smoking cessation: Smoking is among the most consistently documented modifiable behavioral factors associated with accelerated visual aging in epidemiological data.
  • Regular eye examinations: Routine eye care allows for detection of early structural changes before functional impact becomes significant, and is the primary mechanism through which clinically actionable findings are identified.

None of these points constitute personalized clinical advice. A qualified eye care provider is the appropriate resource for guidance on individual screening schedules and any specific concerns.

An elevated polygenic score on this trait is best understood as context — it suggests a genetic background that, in population-level research, correlates with patterns of age-related visual change. It is not a prediction of any individual outcome.

People who learn their genetic profile on this trait may find it useful as one input when thinking about the timing of eye care conversations with a clinician, particularly for establishing a baseline and understanding any family history of visual conditions. Genetic information about population-level tendencies does not replace direct clinical evaluation.

For those interested in general approaches to eye health across the lifespan, established guidance consistently highlights: maintaining protective eyewear habits, not smoking, eating a varied diet with vegetables containing carotenoids, managing systemic conditions such as hypertension and blood sugar that influence vascular health throughout the body (including the retina), and maintaining regular screening with a qualified provider.

A genetics report is a starting point for awareness, not a clinical assessment. The biology of visual aging involves many interacting factors — genetic, vascular, metabolic, environmental — and no single score captures the full picture.

Age-Related Eyesight Decline sits within the Eye & Vision Aging subcategory of Longevity & Aging. Several neighboring traits share biological themes or overlapping genetic architecture:

  • Age-Related Hearing Decline — another sensory aging trait capturing auditory changes with age, with some shared epidemiological risk factors
  • Biological Age Acceleration — a broader aging index reflecting the pace of systemic aging processes
  • Grip Strength — a physical aging marker with connections to musculoskeletal aging trajectories
  • Sleep Duration — sleep quality has associations with a range of aging outcomes including circadian-mediated tissue maintenance
  • Inflammatory Response — systemic inflammation is one proposed pathway in age-related retinal change

Among the genes flagged near the strongest signals for this trait, BMP4 has the broadest annotation across development and structural biology. For more about BMP4's broader role, see the BMP4 gene page.

Frequently Asked Questions

Does a high score on this trait mean eyesight will definitely decline faster with age?

No. A higher polygenic score reflects a genetic background that, in large research studies, is statistically associated with patterns of greater age-related visual change at the population level. Individual outcomes depend on a wide range of factors including environment, lifestyle, overall health, and chance. Genetics is one part of a complex picture, and no score predicts an individual's outcome with certainty. This trait is educational context, not a clinical forecast.

What genes are associated with this trait?

The strongest genomic signals near this trait fall in regions close to BMP3, BMP4, and BMP2 — members of the bone morphogenetic protein family involved in tissue structural development. Additional signals are found near VIPR2, TLL1, ADAMTSL1, RASGRF1, and RGR, a retinal G protein-coupled receptor with a direct role in the visual cycle. These are population-level associations; definitive causal mechanisms have not been established.

How confident is the research behind this trait?

This trait carries a moderate confidence classification. The underlying genomic signals come from a large, well-powered study using UK Biobank data, but the trait is derived from a statistical factor rather than a single direct clinical measurement. The moderate rating reflects that while associations are real, interpretation for any individual requires care. Research in this area continues to develop.

Are there lifestyle changes that might support long-term eye health?

General public health guidance consistently highlights several habits associated with eye health across the lifespan: using UV-protective eyewear outdoors, eating a diet rich in leafy greens and omega-3 sources, not smoking, managing systemic health conditions with a clinician, and maintaining regular eye examinations for baseline monitoring and early detection of any structural changes. These are general health literacy points, not personalized recommendations.

Is this the same as age-related macular degeneration (AMD)?

No. This trait captures broad patterns of age-related visual change as identified through a factor-analytic study of UK Biobank phenotypes. It is not equivalent to age-related macular degeneration, which is a specific clinical condition with its own well-characterized genetic architecture (including well-known signals near CFH and ARMS2/HTRA1). The genetics of broad visual aging overlap partially with but are distinct from those of specific clinical conditions.

Should genetic results on this trait be shared with an eye care provider?

That is a personal decision, but it can be a useful conversation starter — particularly for understanding family history context or thinking about screening timing. A qualified eye care clinician is the appropriate person to interpret any clinical significance of genetic findings in the context of a full examination and medical history. ExomeDNA's genetic reports are wellness products and are not substitutes for clinical evaluation.

References

[1] Carey et al. Principled distillation of UK Biobank phenotype data reveals underlying structure in human variation. Nature Human Behaviour. 2024. PMID: 38965376.

Data sources:

  • GWAS Catalog (NHGRI-EBI, accessed 2026-05-29)
  • Open Targets Platform (CC0 1.0, accessed 2026-05-29)
  • ClinVar (NCBI, accessed 2026-05-29) — entries at 2-star review status or above
  • ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-29)

By the ExomeDNA Research Team

FDA wellness compliance statement: This content is intended for educational and informational purposes only. ExomeDNA's genetic reports are wellness products, not clinical tools, and are not substitutes for professional health guidance. Genetic variants discussed reflect population-level associations from published research. Individual genetic results should be interpreted with the guidance of a qualified healthcare provider.

Browse all traits →